Treatment Options for PAH*
Although there is no cure for pulmonary arterial hypertension (PAH)*, there are several PAH* treatments available. You can work closely with your healthcare team to develop a treatment plan. PAH* is a progressive disease—meaning that it gets worse over time. That's why an early diagnosis is so important.
Several PAH* medications have been approved by the FDA to treat PAH*. You can work with your healthcare professional to determine which medication is appropriate for you.
Tracleer® (bosentan) is one approved PAH* medication. It's pronounced tra • KLEER and is available as a pill taken by mouth. Tracleer is a medication that works differently from many other treatments for PAH*. It is a dual endothelin receptor antagonist (ERA). Tracleer was the first oral ERA approved to treat people with certain types of PAH and has over 10 years of clinical experience.
Medications you may receive in addition to your PAH* treatment
Because PAH* is a severe and chronic disease, treatment can be complex. Many physicians prescribe medications for other conditions associated with PAH*. These may include:
- Anticoagulants—to prevent blood clots in the lungs
- Digoxin—to help the heart pump more effectively (however, this drug has no effect on constricted blood vessels)
- Diuretics—to reduce fluid in the body and reduce swelling in the feet and legs
- Inhaled oxygen—to make more oxygen available to the blood
Be sure to inform your healthcare professional of all the medications you are taking.
Do not take Tracleer with cyclosporine A, a medication used for psoriasis and rheumatoid arthritis, and to prevent rejection of heart or kidney transplants. Using cyclosporine A with Tracleer may increase your chance of side effects. Do not take Tracleer with glyburide. Glyburide is used to treat diabetes and when used with Tracleer it may increase your chance of liver injury.
Tracleer has not been studied in all PAH* patient populations.
Studies showing Tracleer is effective included mainly people with mild to severe symptoms (called NYHA Functional Class II-IV). In these patients, PAH* was caused by: unknown causes (called idiopathic), hereditary causes (a family history), connective tissue diseases (like scleroderma or lupus), or being born with a hole in the heart between the left and the right sides.